Context Therapeutics announces first patient dosed in Phase 1 trial of CTIM-76 for CLDN6-positive cancers. Initial data expected 2026. Context Therapeutics Inc. has announced the dosing of the first ...
Context Therapeutics Inc. (NASDAQ:CNTX) is one of the best penny stocks under $1 to buy now. Earlier in June, Context Therapeutics presented a Trial in Progress poster for its Phase 1 clinical trial ...
RECIST v1.1 in patients with platinum-resistant ovarian cancer ('PROC”) who progressed on a median of 7 prior lines of therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results